Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) CEO Faraz Ali sold 9,748 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.89, for a total transaction of $28,171.72. Following the completion of the sale, the chief executive officer now directly owns 188,331 shares of the company’s stock, valued at approximately $544,276.59. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Tenaya Therapeutics Price Performance
Shares of NASDAQ:TNYA traded down $0.11 during mid-day trading on Friday, reaching $2.89. 449,025 shares of the company were exchanged, compared to its average volume of 454,665. The firm has a market cap of $226.92 million, a price-to-earnings ratio of -1.76 and a beta of 2.43. The firm’s 50-day simple moving average is $3.23 and its 200 day simple moving average is $4.28. Tenaya Therapeutics, Inc. has a 1 year low of $1.66 and a 1 year high of $7.01.
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, research analysts forecast that Tenaya Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tenaya Therapeutics
Analysts Set New Price Targets
TNYA has been the subject of several analyst reports. William Blair initiated coverage on shares of Tenaya Therapeutics in a research note on Monday, June 10th. They issued an “outperform” rating for the company. Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday, July 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.25.
Check Out Our Latest Stock Analysis on TNYA
Tenaya Therapeutics Company Profile
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Featured Articles
- Five stocks we like better than Tenaya Therapeutics
- What is Put Option Volume?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Why Invest in High-Yield Dividend Stocks?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- What is the Dow Jones Industrial Average (DJIA)?
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.